The Use of Combined Motor Imagery and Action Observation to Evaluate the Influence on Functional Parameters Such as Strength, Range of Motion, Pain or Fear of Movement Among Others, in Females Breast Cancer Survivors.

NCT ID: NCT07067710

Last Updated: 2025-07-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

108 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-02-25

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to evaluate the effectivity of the combined motor imagery and action observation therapies to improve functional parameters such as strenght, range of motion, pain or fear of movements among others in relation to upper limb in breast cancer survivors. The main question it aims to answer is: Will a combined therapy of motor imagery and action observation improve the strenght, rang of motion, pain, limb diameter and fear of movement of the upper limb in breast cancer survivor females? The participants will be part of the IM-OA23 proyect that consist on seeing some diferent videos about upper limb mobility and then they'll have to imagine the movements and to performed themselves. Researches will compare two groups (control group and intervention group) to evaluate the diferences between them.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Purpose: The aim of this study is to evaluate the effectivity of a combined motor imagery and action observation protocol at strength, range of motion, limb diamter, and fear of movement of the upper limb of breast cancer survivors.

Methods: A randomised controlled clinical trial will be conducted. Subjects will be randomly assigned to the two randomly assigned to the two treatment groups: intervention (IM-OA23 programme) and control group (usual care).

This study will have pre and post measurements. The intervention consist on a display of diferent videos of upper limb movements and at daily living activities and in a excercise of imagine and doing this movements. The're will be used diferent tools such as a dynamometer, a goniometer, Visual Analogue Scale (VAS) of pain, or TSK questionnaire.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Survivor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IMOA group

The intervention group will participate in the IM-OA23 programme; the combination of motor imagery and action observation therapies.

Group Type EXPERIMENTAL

Motor imagery combined with action observation

Intervention Type OTHER

To observe and imaging one action with a video resource. Not virtual reality.

Control group

The control group will follow the usual care from primary care. There are no care programmes for long term cancer survivors.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Motor imagery combined with action observation

To observe and imaging one action with a video resource. Not virtual reality.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female, over 18 years, have suffered breast cancer, have ended active treatments (chemotherapy, radiotherapy, surgery), have pain or functional limitation or lymphedema at upper limb afected.

Exclusion Criteria

* males, people with active treatments ongoning, other types of cancer, recurrence or metastasis of cancer
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Instituto de Investigación Sanitaria de Navarra (IdiSNA)

UNKNOWN

Sponsor Role collaborator

Fundacion Miguel Servet

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paula Escalada-Hernández, PhD

Role: STUDY_DIRECTOR

Public University of Navarra

Nelia Soto-Ruiz, PhD

Role: STUDY_DIRECTOR

Universidad Pública de Navarra

Pilar Arnal-Vallés, Candidate PhD

Role: PRINCIPAL_INVESTIGATOR

Hospital of Navarra

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Public University of Navarre

Pamplona, Navarre, Spain

Site Status NOT_YET_RECRUITING

Public University of Navarre

Pamplona, Navarre, Spain

Site Status RECRUITING

Public University of Navarre

Pamplona, Navarre, Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pilar Arnal-Vallés, Candidate PhD

Role: CONTACT

+34 948166117

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Pilar Arnal-Vallés, Candidate PhD

Role: primary

+34 948166117

María pilar Arnal Vallés, Candidate PhD

Role: primary

+34 948166117

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PI_2023/81

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

PI_2023/81 Programa IM-OA23

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.